Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Davern Capital Partners, LP
Form 13F · Q2 2026

Davern Capital Partners, LP

CIK 2003147Filed 2026-08-1313F-HR View the filing on EDGAR ↗
$587M
Reported book value
15
Positions
3
Quarters on record
Top 50
Positions

Davern Capital Partners, LP — holdings

Top 15 positions of 15, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1BNTX Biontech Se754,550+147.3%$70M12.0%
2ROIV Roivant Sciences Ltd1.9M+121.3%$68M11.7%
3RPRX Royalty Pharma Plc1.2M+122.3%$65M11.0%
4IONS Ionis Pharmaceuticals Inc798,709+106.4%$63M10.8%
5INSM Insmed Inc559,824+206.6%$60M10.2%
6REGN Regeneron Pharmaceuticals92,640+106.8%$58M9.8%
7LEGN Legend Biotech Corp1.2M−9.4%$34M5.9%
8ALNY Alnylam Pharmaceuticals Inc113,085—$34M5.8%
9NTRA Natera Inc118,975−17.4%$32M5.5%
10GPCR Structure Therapeutics Inc446,059+252.7%$24M4.1%
11MLYS Mineralys Therapeutics Inc858,753+92.0%$23M4.0%
12VERA Vera Therapeutics Inc498,832—$21M3.6%
13GENB Generate Biomedicines Inc824,679+39.4%$14M2.4%
14PRCT Procept Biorobotics Corp464,920+78.0%$10M1.8%
15AVTX Avalo Therapeutics Inc468,666—$9M1.5%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.